Medigen Biotechnology (3176) — Capital Reinvestment Ratio
Medigen Biotechnology (3176) has a Capital Reinvestment Ratio of 0.06x as of December 2024, meaning it reinvests 0% of its operating cash flow (NT$156.75 Million) in capital expenditures (NT$9.09 Million). Check 3176 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Medigen Biotechnology Capital Reinvestment Ratio (2003–2024)
This chart tracks Medigen Biotechnology's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see Medigen Biotechnology (3176) cash flow conversion.
Annual Capital Reinvestment Ratio for Medigen Biotechnology (2003–2024)
Year-by-year Capital Reinvestment Ratio for Medigen Biotechnology from 2003 to 2024. See Medigen Biotechnology free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.55x | NT$37.92 Million | NT$58.68 Million | ▲ +453.9% |
| 2021 | 0.28x | NT$517.45 Million | NT$144.55 Million | ▼ -84.1% |
| 2015 | 1.75x | NT$294.18 Million | NT$515.25 Million | ▲ +4303.1% |
| 2005 | 0.04x | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$445.46 Million | NT$3.96 Million | — |